Guardant Health Inc (NASDAQ:GH) insider Richard B. Lanman sold 5,764 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $67.99, for a total transaction of $391,894.36.
Guardant Health stock opened at $64.65 on Thursday. Guardant Health Inc has a 1 year low of $31.06 and a 1 year high of $112.21. The firm has a 50 day moving average price of $66.74 and a 200 day moving average price of $80.35.
Guardant Health (NASDAQ:GH) last released its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The firm had revenue of $53.98 million during the quarter, compared to the consensus estimate of $35.97 million. During the same period in the previous year, the firm earned ($1.75) earnings per share. Guardant Health’s revenue was up 178.5% compared to the same quarter last year. On average, research analysts predict that Guardant Health Inc will post -1.27 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GH. FMR LLC grew its stake in Guardant Health by 28.3% during the first quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after buying an additional 102,483 shares during the period. First Trust Advisors LP grew its stake in Guardant Health by 0.4% during the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after buying an additional 264 shares during the period. Ipswich Investment Management Co. Inc. purchased a new stake in Guardant Health during the second quarter worth approximately $1,486,000. Xact Kapitalforvaltning AB purchased a new stake in Guardant Health during the second quarter worth approximately $354,000. Finally, Handelsbanken Fonder AB purchased a new stake in Guardant Health during the second quarter worth approximately $8,029,000. Institutional investors own 79.18% of the company’s stock.
A number of equities research analysts recently issued reports on GH shares. ValuEngine upgraded shares of Guardant Health from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Canaccord Genuity restated a “buy” rating and issued a $125.00 target price on shares of Guardant Health in a report on Thursday, October 24th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Cowen set a $110.00 target price on shares of Guardant Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Zacks Investment Research upgraded shares of Guardant Health from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a report on Wednesday, October 9th. Seven analysts have rated the stock with a buy rating, Guardant Health presently has a consensus rating of “Buy” and an average target price of $104.40.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Read More: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.